Glycemia in Diabetic Elders Trial

• Status: Terminated
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a pilot randomized controlled trial of 30 elderly type 2 diabetes patients conducted at the MODEL Clinical Research (MODEL), Research Division of Bay West Endocrinology Associates in Baltimore, Maryland. The investigators hypothesized that compared to a regimen base solely on traditional drugs, a regimen including newer drugs will achieve glycemic target faster and induce less hypoglycemia, weight gain, and other side effects, over the short run.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Incretins; Insulin; Insulin, Globin Zinc; Islet Amyloid Polypeptide; Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetics diagnosed for at least 6 months

• Patients ages ≥ 65 years and older

• Active patients in the Bay West Endocrinology practice

• Inadequately controlled on oral agents and/or basal insulin with HbA1c between 8.0% and 12%

• Eligible for randomization to either treatment group

• Patients willing to follow either treatment arm including regimen using one or more injectables

• Patients to have an English Reading Level of Grade 6 or above

• Patients residing at home

Exclusion Criteria:

• Unwilling to use a regimen that may contain using one or more injections

• Using short acting insulin prior to the study

• Using GLP-1 in past 10 weeks

• History of hypoglycemia unawareness or episodes needing emergency intervention

• End-stage renal disease

• Dementia

• Blindness

• Terminal illness